[1]
|
Chakraborty, P., George, J.T., Woodward, W.A., et al. (2021) Gene Expression Profiles of Inflammatory Breast Cancer Reveal High Heterogeneity across the Epithelial-Hybrid-Mesenchymal Spectrum. Translational Oncology, 14, Article ID: 101026. https://doi.org/10.1016/j.tranon.2021.101026
|
[2]
|
Hance, K.W., Anderson, W.F., Devesa, S.S., et al. (2005) Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Re-sults Program at the National Cancer Institute. JNCI: Journal of the National Cancer Institute, 97, 966-975. https://doi.org/10.1093/jnci/dji172
|
[3]
|
Yamauchi, H., Woodward, W.A., Valero, V., et al. (2012) Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 17, 891-899. https://doi.org/10.1634/theoncologist.2012-0039
|
[4]
|
Masuda, H., Brewer, T.M., Liu, D.D., et al. (2014) Long-Term Treatment Efficacy in Primary Inflammatory Breast Cancer by Hormonal Receptor- and HER2-Defined Sub-types. Annals of Oncology, 25, 384-391.
https://doi.org/10.1093/annonc/mdt525
|
[5]
|
Anderson, W.F., Schairer, C., Chen, B.E., et al. (2005) Epidemiology of Inflammatory Breast Cancer (IBC). Breast Disease, 22, 9-23. https://doi.org/10.3233/BD-2006-22103
|
[6]
|
Pence, L.J., Kourtidis, A., Feathers, R.W., et al. (2021) PLEKHA7, an Apical Adherens Junction Protein, Suppresses Inflammatory Breast Cancer in the Context of High E-Cadherin and p120-Catenin Expression. International Journal of Molecular Sciences, 22, 1275. https://doi.org/10.3390/ijms22031275
|
[7]
|
Hester, R.H., Hortobagyi, G.N. and Lim, B. (2021) Inflammatory Breast Cancer: Early Recognition and Diagnosis Is Critical. Am J Obstet Gynecol, 225, 392-396. https://doi.org/10.1016/j.ajog.2021.04.217
|
[8]
|
王欣冉, 张建国. 炎性乳腺癌的诊断与治疗进展[J]. 中国现代普通外科进展, 2019, 22(4): 308-311.
|
[9]
|
Van Der Auwera, I., Limame, R., Van Dam, P., et al. (2010) Integrated miRNA and mRNA Expression Profiling of the Inflammatory Breast Cancer Subtype. British Journal of Cancer, 103, 532-541. https://doi.org/10.1038/sj.bjc.6605787
|
[10]
|
Lehman, H.L., Van Laere, S.J., Van Golen, C.M., et al. (2012) Regulation of Inflammatory Breast Cancer Cell Invasion through Akt1/PKBα Phosphorylation of RhoC GTPase. Molec-ular Cancer Research, 10, 1306-1318.
https://doi.org/10.1158/1541-7786.MCR-12-0173
|
[11]
|
Bozzetti, F., Saccozzi, R., De Lena, M., et al. (1981) In-flammatory Cancer of the Breast: Analysis of 114 Cases. Journal of Surgical Oncology, 18, 355-361. https://doi.org/10.1002/jso.2930180405
|
[12]
|
Schlichting, J.A., Soliman, A.S., Schairer, C., et al. (2012) Inflam-matory and Non-Inflammatory Breast Cancer Survival by Socioeconomic Position in the Surveillance, Epidemiology, and End Results Database, 1990-2008. Breast Cancer Research and Treatment, 134, 1257-1268. https://doi.org/10.1007/s10549-012-2133-2
|
[13]
|
Bertucci, F., Ueno, N.T., Finetti, P., et al. (2014) Gene Expression Profiles of Inflammatory Breast Cancer: Correlation with Response to Neoadjuvant Chemotherapy and Metastasis-Free Survival. Annals of Oncology, 25, 358-365.
https://doi.org/10.1093/annonc/mdt496
|
[14]
|
Genet, D., Lejeune, C., Bonnier, P., et al. (2007) Concomitant Inten-sive Chemoradiotherapy Induction in Non-Metastatic Inflammatory Breast Cancer: Long-Term Follow-Up. British Jour-nal of Cancer, 97, 883-887.
https://doi.org/10.1038/sj.bjc.6603987
|
[15]
|
Perez, C.A., Graham, M.L., Taylor, M.E., et al. (1994) Management of Locally Advanced Carcinoma of the Breast. I. Noninflammatory. Cancer, 74, 453-465. https://doi.org/10.1002/cncr.2820741335
|
[16]
|
Dawood, S., Merajver, S.D., Viens, P., et al. (2011) International Expert Panel on Inflammatory Breast Cancer: Consensus Statement for Standardized Diagnosis and Treatment. Annals of Oncology, 22, 515-523.
https://doi.org/10.1093/annonc/mdq345
|
[17]
|
Harvey, H.A., Lipton, A., Lawrence, B.V., et al. (1982) Estrogen Re-ceptor Status in Inflammatory Breast Carcinoma. Journal of Surgical Oncology, 21, 42-44. https://doi.org/10.1002/jso.2930210111
|
[18]
|
Nguyen, D.M., Sam, K., Tsimelzon, A., et al. (2006) Molecular Het-erogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype. Clinical Cancer Research, 12, 5047-5054.
https://doi.org/10.1158/1078-0432.CCR-05-2248
|
[19]
|
Zell, J.A., Tsang, W.Y., Taylor, T.H., et al. (2009) Prog-nostic Impact of Human Epidermal Growth Factor-Like Receptor 2 and Hormone Receptor Status in Inflammatory Breast Cancer (IBC): Analysis of 2,014 IBC Patient Cases from the California Cancer Registry. Breast Cancer Research, 11, Article No. R9. https://doi.org/10.1186/bcr2225
|
[20]
|
Walshe, J.M. and Swain, S.M. (2005) Clinical Aspects of In-flammatory Breast Cancer. Breast Disease, 22, 35-44.
https://doi.org/10.3233/BD-2006-22105
|
[21]
|
Harbeck, N. and Gnant, M. (2017) Breast Cancer. Lancet, 389, 1134-1150.
https://doi.org/10.1016/S0140-6736(16)31891-8
|
[22]
|
Braal, C.L., Jongbloed, E.M., Wilting, S.M., et al. (2021) In-hibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 81, 317-331.
https://doi.org/10.1007/s40265-020-01461-2
|
[23]
|
Slade, D. (2020) PARP and PARG Inhibitors in Cancer Treat-ment. Genes & Development, 34, 360-394.
https://doi.org/10.1101/gad.334516.119
|
[24]
|
Nunnery, S.E. and Mayer, I.A. (2020) Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs, 80, 1685-1697. https://doi.org/10.1007/s40265-020-01394-w
|